| Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation VJ Nijenhuis, J Brouwer, R Delewi, RS Hermanides, W Holvoet, ... New England Journal of Medicine 382 (18), 1696-1707, 2020 | 160 | 2020 |
| Aspirin with or without clopidogrel after transcatheter aortic-valve implantation J Brouwer, VJ Nijenhuis, R Delewi, RS Hermanides, W Holvoet, ... New England Journal of Medicine 383 (15), 1447-1457, 2020 | 159 | 2020 |
| How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3) FW Thielen, G Van Mastrigt, LT Burgers, WM Bramer, HJM Majoie, ... Expert Review of Pharmacoeconomics & Outcomes Research 16 (6), 705-721, 2016 | 62 | 2016 |
| Long-term economic consequences of child maltreatment: a population-based study FW Thielen, M Ten Have, R de Graaf, P Cuijpers, A Beekman, S Evers, ... European child & adolescent psychiatry 25 (12), 1297-1305, 2016 | 33 | 2016 |
| Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens LEM Oosten, MED Chamuleau, FW Thielen, LC de Wreede, C Siemes, ... Annals of hematology 97 (2), 255-266, 2018 | 27 | 2018 |
| Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view FW Thielen, A van Dongen‐Leunis, AMM Arons, JR Ladestein, ... European journal of haematology 105 (2), 203-215, 2020 | 14 | 2020 |
| Kindermishandeling: economische gevolgen op lange termijn1 P Speetjens, F Thielen, M Ten Have, R De Graaf, F Smit Tijdschrift voor psychiatrie 58 (10), 706-711, 2016 | 12 | 2016 |
| Health economic aspects of chimeric antigen receptor T-cell therapies for hematological cancers: present and future R Heine, FW Thielen, M Koopmanschap, MJ Kersten, H Einsele, U Jaeger, ... Hemasphere 5 (2), 2021 | 10 | 2021 |
| Designing and testing of a health-economic Markov model for prevention and treatment of early psychosis BFM Wijnen, FW Thielen, S Konings, T Feenstra, M Van Der Gaag, ... Expert review of pharmacoeconomics & outcomes research 20 (3), 269-279, 2020 | 5 | 2020 |
| Second‐line treatment for acute graft‐versus‐host disease with mesenchymal stromal cells: A decision model FW Thielen, HM Blommestein, LEM Oosten, FG Calkoen, AC Lankester, ... European Journal of Haematology 101 (5), 676-683, 2018 | 4 | 2018 |
| Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma FW Thielen, NC Büyükkaramikli, R Riemsma, D Fayter, N Armstrong, ... Pharmacoeconomics 37 (8), 975-984, 2019 | 3 | 2019 |
| Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view FW Thielen, MJ Kersten, P Kuizenga, M Hoogendoorn, EFM Posthuma, ... Expert review of anticancer therapy 21 (12), 1411-1422, 2021 | 2 | 2021 |
| Cost of health care for paediatric patients with sickle cell disease: an analysis of resource use and costs in a European country FW Thielen, ME Houwing, MH Cnossen, IA al Hadithy‐Irgiztseva, ... Pediatric Blood & Cancer 67 (9), e28588, 2020 | 2 | 2020 |
| Using appropriate methods in cost-effectiveness analyses: the case of allogeneic hematopoietic cell transplantation in sickle cell disease FW Thielen, HM Blommestein, CA Uyl-de Groot Biology of Blood and Marrow Transplantation 22 (11), 2109-2110, 2016 | 2 | 2016 |
| Policy evaluation and behavioral economics K Ruggeri, JP Stuhlreyer, JE Immonen, S Mareva, M Friedemann, AF Paul, ... Psychology and Behavioral Economics, 226-246, 2021 | 1 | 2021 |
| Child maltreatment: long-term economic consequences and implications P Speetjens, F Thielen, M Ten Have, R de Graaf, F Smit Tijdschrift voor Psychiatrie 58 (10), 706-711, 2016 | 1 | 2016 |
| Current Challenges in Health Technology Assessment: Assessing costs and cost-effectiveness of novel treatments in haemato-oncology F Thielen | | 2020 |
| The Cost of Healthcare for Pediatric Patients with Sickle Cell Disease ME Houwing, F Thielen, APJ de Pagter, JA Hazelzet, H Blommestein, ... Blood 134, 1030, 2019 | | 2019 |
| Policy evaluation Kai Ruggeri, Julia P. Stuhlreyer, Johanna Immonen, Silvana Mareva ... Behavioral Insight for Public Policy: Concepts and Cases, 288, 2018 | | 2018 |
| Second-Line Treatment for Steroid-Refractory Graft-Versus-Host Disease with Mesenchymal Stromal Cells. A Conceptual Disease Model F Thielen, HM Blommestein, L Oosten, W Fibbe, K Le Blanc, F Locatelli, ... Value in Health 20 (9), A545-A546, 2017 | | 2017 |
Silvia MAA EversMaastricht UniversityVerified email at maastrichtuniversity.nl
